Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung function

•People with CF benefit from LUMA-IVA at all levels of baseline lung function.•Patients with ppFEV190 are less likely to show ppFEV1 improvement.•Individual patients with ppFEV1 may show large improvement in ppFEV1.•Most patients with ppFEV1

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of cystic fibrosis 2021-03, Vol.20 (2), p.220-227
Hauptverfasser:	Burgel, Pierre-Régis, Durieu, Isabelle, Chiron, Raphaël, Mely, Laurent, Prevotat, Anne, Murris-Espin, Marlene, Porzio, Michele, Abely, Michel, Reix, Philippe, Marguet, Christophe, Macey, Julie, Sermet-Gaudelus, Isabelle, Corvol, Harriet, Bui, Stéphanie, Biouhee, Tiphaine, Hubert, Dominique, Munck, Anne, Lemonnier, Lydie, Dehillotte, Clémence, Silva, Jennifer Da, Paillasseur, Jean-Louis, Martin, Clémence
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aminophenols - therapeutic use Aminopyridines - therapeutic use Benzodioxoles - therapeutic use Chloride Channel Agonists - therapeutic use Cystic Fibrosis - drug therapy Cystic Fibrosis - physiopathology Disease Progression Drug Combinations Female France Humans Life Sciences Male Quinolones - therapeutic use Respiratory Function Tests
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	•People with CF benefit from LUMA-IVA at all levels of baseline lung function.•Patients with ppFEV190 are less likely to show ppFEV1 improvement.•Individual patients with ppFEV1 may show large improvement in ppFEV1.•Most patients with ppFEV1
ISSN:	1569-1993 1873-5010
DOI:	10.1016/j.jcf.2020.06.012